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The cytochrome P450 RauA from Rhodococcus erythropolis JCM 6824 catalyzes the hydroxylation of a
nitrogen atom in the quinolone ring of aurachin, thereby conferring strong antibiotic activity on the
aurachin alkaloid. Here, we report the crystal structure of RauA in complex with its substrate, a
biosynthetic intermediate of aurachin RE. Clear electron density showed that the quinolone ring
is oriented parallel to the porphyrin plane of the heme cofactor, while the farnesyl chain curls into
a U-shape topology and is buried inside the solvent-inaccessible hydrophobic interior of RauA. The
nearest atom from the heme iron is the quinolone nitrogen (4.3 Å), which is consistent with RauA
catalyzing the N-hydroxylation of the quinolone ring to produce mature aurachin RE.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction antibiotic activity against a wide range of gram-positive bacteriaAntibiotics play an important role in the treatment of severe
bacterial infections. Investigations into new antibiotic regimens
are required because of the emergence of multi-drug resistance,
as well as new pathogenic bacteria. Aurachin alkaloids are rare
compounds found in nature and are composed of a quinolone ring
and farnesyl chain. Two phylogenetically unrelated bacterial spe-
cies, Rhodococcus and Stigmatella, are known to synthesize several
molecular variations of aurachin alkaloids [1–7]. A previous study
indicated that aurachins could be potent inhibitors of mitochon-
drial respiration because of their structural similarity with
menaquinone (vitamin K2), the sole respiratory quinone for most
eubacteria [8]. The enzymes that catalyze the synthesis of
menaquinone are potential targets for the development of novel
antibacterial drugs [9].
Aurachin RE is an aurachin alkaloid isolated from Rhodococcus
erythropolis JCM 6824 (Fig. 1), and it exhibits relatively strong[6]. Recent studies revealed that aurachin RE exhibits inhibitory
activity against 1,4-dihydroxy-2-naphthoate prenyltransferase
(MenA) of Mycobacterium tuberculosis, which is an essential en-
zyme in the menaquinone biosynthesis pathway [10–12]. There-
fore, the antibiotic property of aurachin RE might be caused by
the inhibition of menaquinone biosynthesis as well as the respira-
tory chain reaction itself [12]. We recently identiﬁed the operon for
aurachin RE biosynthesis (rauA–rauH) of R. erythropolis JCM 6824,
and gene disruption experiments revealed that rauA, which
encodes a cytochrome P450 monooxygenase, is crucial for its anti-
biotic activity [7]. In addition, we found that recombinant P450
RauA catalyzes nitrogen hydroxylation of the quinolone ring and
produces the mature antibiotic aurachin RE. Therefore, RauA is
considered to be the ﬁnal enzyme that completes the biosynthesis
of aurachin RE [7]. Interestingly, the P450 gene functionally corre-
sponding to RauA has not been found in the genome sequence of
Stigmatella aurantiaca Sg a15 [4], and thus, RauA is likely a unique
entity speciﬁcally evolved for the recognition of the aurachin
skeleton in R. erythropolis.
P450s are heme-containing enzymes widely found in eukary-
otes, bacteria, and archaea and play a role in diverse biological
functions, such as biosynthesis of steroids, lipids, antibiotics,
detoxiﬁcation of xenobiotics, and drug metabolism [13]. A typical
Fig. 1. Enzymatic reaction catalyzed by RauA. Aurachin RE biosynthetic interme-
diate is the substrate for RauA. The structure of vitamin K2 (Menaquinone-4, MK-4)
is also shown. The ﬁgure was created using ChemDraw (CambridgeSoft).
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an activated oxygen atom generated from molecular oxygen (O2)
into the substrate compound using two electrons sequentially
delivered from the redox partner protein and an additional two
protons [14]. P450s form a conserved 3D structure known as the
‘‘P450-fold’’; however, the substrate-binding pocket in the vicinity
of the heme cofactor has evolved to accommodate a wide variety of
compounds. In bacteria, most P450s are distributed in actinomy-
cetes and are considered to be involved in the biosynthesis of cer-
tain secondary metabolites, including antibiotics, and metabolism
of exogenous compounds. Currently, a number of P450 genes have
been identiﬁed because of the recent advances in genome analysis.
However, the biological function, substrate speciﬁcity, and 3D
structures of most P450s remain unknown.
Here, we report the enzymatic and structural characterization
of a new bacterial P450, RauA. Since aurachins are rare compounds
found in nature, it is of interest to elucidate how RauA recognizes
the aurachin skeleton. RauA is also unique in that it catalyzes the
hydroxylation of the cyclic nitrogen atom, although some P450s
are known to catalyze N-hydroxylation of amines or amidines
[15,16]. Our structure clearly showed that the aurachin RE inter-
mediate is buried inside the active-site pocket with the nitrogen
atom of its quinolone moiety oriented toward the heme iron.
2. Materials and methods
2.1. Overexpression and puriﬁcation of RauA
Gene cloning and analysis of recombinant protein expression
were performed according to a previously described method [7].
Brieﬂy, the rauA gene was cloned into the NdeI and XhoI sites ofthe pET26 expression vector, and the recombinant RauA containing
a C-terminal His6-tag was expressed in Escherichia coli BL21-
CodonPlus(DE3)-RIL cells. The expression of RauA was induced
with 0.1 mM isopropyl b-D-thiogalactopyranoside in LB medium
supplemented with FeSO4 (100 lM) and 5-aminolevulinic acid
(80 lg/ml) [17]. The RauA was puriﬁed by Ni-afﬁnity chromatogra-
phy followed by anion-exchange chromatography [7]. For
crystallization, the purity was increased by gel-ﬁltration chroma-
tography with a Sephacryl S-100 column (GE-Healthcare) using a
solution containing 20 mM Tris pH 7.5, 150 mM NaCl, and 10%
glycerol. A carbon monoxide binding assay [18] was performed
to verify the RauA concentration.
2.2. Enzyme activity measurement and kinetic analysis
Aurachin RE biosynthetic intermediate (substrate) was obtained
from the culture media of rauA gene disruption mutant strain of R.
erythropolis as previously described [7]. The enzyme assay was per-
formed with reconstitution experiments. The reaction mixture
contained 1.0–2.5 lM RauA, 1.0–20.0 lM substrate, 100 lg/ml
spinach ferredoxin (Fdx) (Sigma–Aldrich), 0.1 U/ml spinach
ferredoxin reductase (FdxR) (Sigma–Aldrich), 3 U/ml D-glucose
dehydrogenase (TOYOBO), 2 mM NADPH, and 60 mM D-glucose
in a total volume of 200 ll of reaction buffer (50 mM Tris–HCl,
pH 7.5). After pre-incubation at 30 C for 2 min, the reaction was
initiated by the addition of NADPH, followed by incubation at
30 C for the appropriate period (2–5 min). The reaction was termi-
nated by extracting once with 800 ll of ethyl acetate. The resulting
organic extract was dried and re-dissolved in 100 ll of methanol.
The methanol solution was analyzed by HPLC (high-performance
liquid chromatography) using the same procedure as previously
described [7]. The molar quantity of aurachin RE and its intermedi-
ate was estimated on the basis of the previously reported molar
absorption coefﬁcient for aurachin D at one of its major absorption
peaks (334 nm) [1]. The Km and kcat values were estimated from
Michaelis–Menten kinetics using the KaleidaGraph (Synergy Soft-
ware), after triplicate experiments with varying substrate
concentrations.
2.3. Substrate binding assay
The substrate-induced spectral shift was monitored using a JAS-
CO V-630 spectrophotometer with a 1-cm path length quartz cell.
The aurachin RE intermediate (substrate) was dissolved in
dimethyl sulfoxide (DMSO) at concentrations ranging from 0 to
10 lM, and 10 ll of the substrate solution was added to 990 ll
of a reaction mixture containing 2.5 lM RauA and 20 mM Tris–HCl,
pH 7.5. Spectral titrations with 0–10 lM substrate were performed
at 25 C. The equation DA = DAmax([S]/([S] + Kd)) was ﬁtted to the
experimental data using the nonlinear least squares ﬁtting
program (SOLVER; http://www.solver.com/), where [S] is the free
substrate concentration. The [S] was obtained as [S] = [S]total -
 [ES] = [S]total  ([E]DA/DAmax), where [S]total is the total
concentration of substrate, [ES] is the concentration of
enzyme–substrate complex, and [E] is the total concentration of
enzyme [19].
2.4. Crystallization
All crystallization experiments were performed at 293 K using
the vapor-diffusion technique. Prior to crystallization, the protein
solution was pre-incubated overnight at 277 K with a 10-fold
molar excess of substrate. The protein solution was mixed with
an equal volume of precipitant solution and equilibrated against
the reservoir containing the same precipitant solution. RauA was
crystallized using a precipitant solution containing 0.1 M MES pH
Table 1
Crystallographic parameters and reﬁnement statistics.
Data collection statistics
Beamline AR-NW12A
Wavelength (Å) 1.0000
Resolution (Å) 50–2.19 (2.31–2.19)a
Unit-cell dimensions
a, b, c (Å) 41.5 100.0, 52.3
a, b, c () 90.0, 108.7, 90.0
Space group P21
Observed reﬂections 75,296
Unique reﬂections 20,745
Rmerge
b 0.056 (0.335)a
Completeness (%) 99.5 (99.1)a
Redundancy 3.6 (3.5)a
Mean I/r (I) 11.4 (3.0)a
Reﬁnement statistics and model quality
Resolution range (Å) 50–2.19
Rwork
c 0.214
Rfree
d 0.263
Total number of atoms (all/protein/heme/AUI/
solvent)e
3203/3078/43/28/54
Average B-factor (all/protein/heme/AUI/solvent)
(Å2)e
55.7/56.6/26.3/41.3/
38.4
rmsd bond distances (Å) 0.013
rmsd bond angles () 2.39
Ramachandran plot (favored/allowed/outliers) (%) 89.4/10.6/0.0
a Values in parentheses refer to data in the highest resolution shell (2.31–2.19 Å).
b Rmerge =Rh Ri |Ih,i  hIhi| / RhRi Ih,i, where hIhi is the mean intensity of a set of
equivalent reﬂections.
c Rwork = R |Fobs  Fcalc|/R Fobs for 95% of the reﬂection data used in the reﬁne-
ment. Fobs and Fcalc are observed and calculated structure factor amplitudes,
respectively.
d Rfree is the equivalent of Rwork, except that it was calculated for a randomly
chosen 5% test set excluded from reﬁnement.
e AUI, PDB chemical identiﬁer for aurachin RE intermediate.
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performed at the Photon Factory (PF) AR-NW12A using a charge-
coupled device (CCD) detector (ADSC). For the X-ray diffraction
study, the crystal was brieﬂy soaked into a precipitant solution
supplemented with 20% glycerol and ﬂash-cooled in a liquid nitro-
gen gas stream at 100 K. The diffraction data were processed using
the program iMosﬂm/SCALA [20,21]. The crystal belongs to the
space group P21, with unit-cell dimensions a = 41.5, b = 100.0,
c = 52.3 Å, a = 90.0, b = 108.7 and c = 90.0.
2.5. Structure determination
The structure of RauA was solved by molecular replacement
with the program PHASER [22] using the atomic coordinates of
the truncated P450 BioI (PDB code, 3EJD [23]) as a search model.
A clear solution for one monomer in the asymmetric unit was
obtained. The iterative model reﬁnement and manual model cor-
rections were performed using the program REFMAC5 [24] and
the graphic program Coot [25]. The stereochemical quality of
the ﬁnal reﬁned models was assessed using PROCHECK [26].
Molecular drawings were prepared using the program PyMOL
(http://www.pymol.org/). Crystallographic parameters and model
reﬁnement statistics are summarized in Table 1. The atomic
coordinates and structure factor amplitudes of RauA have been
deposited in the RCSB Protein Data Bank under the accession code
3WEC.
2.6. Phylogenetic analysis
Sequences with homology to RauA were obtained from the
bacterial P450 database (http://drnelson.uthsc.edu/Cyto-
chromeP450.html) or NCBI (http://www.ncbi.nlm.nih.gov/) viathe BLAST explorer. The phylogenetic tree was constructed using
the Phylogeny.fr server [27] using the default settings.3. Results and discussion
3.1. Enzyme assay and spectroscopic characterization
Firstly, we describe the results of the kinetic and spectroscopic
analysis of RauA, by using the biosynthetic intermediate of aura-
chin RE as a substrate. The in vitro reconstituted enzyme assay
was carried out with spinach ferredoxin and ferredoxin reductase
as the electron donor for the recombinant RauA, and the reaction
product (mature aurachin RE) was detected by HPLC analysis.
The kcat and Km values were 3.97 ± 0.45 min1 and
0.82 ± 0.12 lM, respectively (Supplemental Fig. 1). These values
are comparable to those of other bacterial and mammalian P450s
that metabolize highly hydrophobic compounds (see e.g., [17,28–
32]; Supplemental Table 1). The UV–Vis spectral analysis also
showed that RauA exhibited high binding afﬁnity to the aurachin
RE intermediate, with an estimated dissociation constant (Kd) of
0.12 lM (Fig. 2). High substrate binding afﬁnity suggests that RauA
is specialized for the recognition of the aurachin RE intermediate.
Binding of substrate to P450s is known to induce a change in
the absorption spectrum caused by a transformation in the spin
state of the heme iron. Typically, the substrate-free resting P450s
are present in a low-spin ferric state, where water is coordinated
to the heme iron as the sixth ligand. The water moves away when
the substrate is bound, which induces a change in the spin state of
the heme iron from low to high spin. Most P450s show an absorp-
tion peak (Soret peak) at around 420 nm in the low-spin state,
which shifts to around 390 nm in the high-spin state: this phenom-
enon is known as a ‘‘type I spectral change’’ [33]. The absorption
spectrum of RauA in the absence of the aurachin RE intermediate
showed a Soret peak at 421 nm, indicating that the heme iron of
the RauA is present in the typical, low-spin resting state. The addi-
tion of substrate unambiguously induced the type-I spectral
change, but the absorption spectrum in the presence of a molar ex-
cess of substrate showed a broad peak from 390 to 420 nm (Fig. 2).
One possible explanation is that the spin state of the heme iron is
unstable and might be present as a mixture of low-spin and high-
spin in the presence of the substrate. A type II spectral change can
also occur when the nitrogen atom is coordinated to the heme iron
as the sixth ligand [33], which is characterized by a decrease in
absorption at around 400 nm accompanied by an increase at
425 nm. However, the type II spectral changes were not observed
in this study.
3.2. Overall structure of RauA
The crystal structure of RauA was determined in complex with
the aurachin RE intermediate (substrate) at 2.19 Å resolution. Crys-
tallization of the substrate-free RauA was also attempted. How-
ever, it did not yield a good quality single crystal suitable for X-
ray structure determination. The RauA structure was solved by
molecular replacement method using the truncated atomic model
of P450 BioI (CYP107H1) [23] as the search model. The asymmetric
unit contains one monomer of RauA that deﬁnes the continuous
electron density map, except for the 10 residues at the N-terminal
and the C-terminal His-tag regions. The atomic model consists of
one polypeptide-chain (residues 11–411), one heme ligand, one
substrate, and 54 water molecules, and was reﬁned with a crystal-
lographic R factor and Rfree factor of 21.4% and 26.3%, respectively.
X-ray data collection and reﬁnement statistics are summarized in
Table 1. The structure exhibits the typical P450-fold consisting of
14 a-helices (aA, aB, aB0, aC–aM) and 8 b-strands (bA–bH)
Fig. 2. Substrate-binding spectral assay. (A) Shown is the spectral change of P450
RauA upon the addition of the aurachin RE intermediate. Strong absorption peaks
around 320 nm originate from the aurachin alkaloid, as previously reported [1]. (B)
The best-ﬁt titration curve to a single-binding site model is graphed. The curve was
generated by nonlinear regression, as described in the materials and methods.
Fig. 3. Ribbon diagram of the overall structure of RauA. The a-helices and b-strands
are labeled alphabetically from N- to C-terminus (aA–aM and bA–bH). The
a-helices, b-strands, and loops are colored in red, yellow, and green, respectively.
The heme cofactor embedded in the center of the molecule is shown as a sphere,
and the bound substrate is shown as a stick model. The mobile moieties of the
P450-fold, the BC-loop and FG-loop, are colored in light blue and dark blue,
respectively. The C-terminal loop partially creating the substrate-binding pocket is
colored in cyan.
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smaller b-strand rich domain and larger a-helix rich domain. The
heme cofactor is embedded inside the core of the molecule—sand-
wiched between the distal I-helix and proximal L-helix. The heme
iron is probably reduced by synchrotron radiation as observed in
some studies (e.g., [34]). The propionate groups of the heme cofac-
tor interact with the side chains of Arg305, His108, and His359. The
thiol group of Cys361 is coordinated to the heme iron on the
proximal side with a distance of 2.4 Å. These residues are well con-
served among all P450 sequences (Supplemental Fig. 2). The highly
conserved Thr and its neighboring Asp residues in the I-helix are
known to be important for oxygen activation [35]. In the RauA
structure, the corresponding residues are Thr257 and Glu256,
respectively (Supplemental Fig. 2).
3.3. Comparison with other related bacterial P450s
We performed a structural homology search using the DALI ser-
ver [36], which showed that the most structurally homologous
P450 is the vitamin D3 hydroxylase (Vdh; CYP107BR1) in an open
conformation (PDB code, 3A4G) [37], with a root mean square
deviation (rmsd) of 2.1 Å for the 365 Ca atoms (Z score, 44.6).P450 EryK (CYP113A1; PDB code, 2WIO) [38], PikC (CYP107L1;
PDB code, 2BVJ) [39], and CYP164B2 (PDB code, 3R9C) [40] also
show relatively high structural homology to RauA, with an rmsd
ranging from 2.2 to 2.7 Å. Structure superimposition showed that
the core structure of the RauA is similar to the structures of those
homologous P450s (Supplemental Fig. 3); however, structural dif-
ferences are also present. The most signiﬁcant structural differ-
ences are located in the two loop regions—a loop between aB
and aC (BC-loop) and between aF and aG (FG-loop) (Fig. 3 and
Supplemental Fig. 3)—which are generally known as the mobile
moieties of the P450-fold involved in substrate recognition. The
curved F-helix of RauA lies across the I-helix, and its C-terminal
end reaches an almost vertical position from the heme iron, with
a distance of 10 Å. The polypeptide chain of the FG-loop forms an
extended conformation and partly builds the substrate-binding
pocket. The BC-loop region of RauA forms an additional a-helix
(aB0), which is not found in the structures of Vdh, EryK, and PikC
(Supplemental Fig. 3). The RauA BC-loop completely closes the
gap between the b-strand rich domain and the FG-loop, and thus,
the substrate-binding pocket is occluded from the solvent.
An NCBI BLAST search showed that there is one hypothetical
P450 in Streptomyces sulphureus (SsP450; NCBI accession number,
WP_016906746) with an amino acid sequence identity of 45% to
RauA. Sequence identities with other higher ranked P450s are all
below 33%. The BLAST search against the bacterial P450 database
[41] showed that some P450s from the Streptomyces, Mycobacte-
rium, and Frankia species are also homologous to RauA but with
amino acid sequence identity of no more than 33%. Notably, 18
out of the top 20 sequences belong to CYP107, CYP164, or
CYP233 families, with sequence identities ranging from 28% to
33%. These results suggest that RauA is located on the periphery
of the CYP107/CYP164/CYP233 clusters. We constructed a phyloge-
netic tree with the sequences of SsP450, CYP107, CYP164, and
CYP233, which revealed that RauA and SsP450 are closely related
and do not overlap with the CYP107, CYP164, and CYP233 clusters
Fig. 4. Active-site structure of RauA. (A) AnmF0DFc omit map for the bound substrate (aurachin RE intermediate) and the water molecule (Wat601) is shown. The map was
contoured at a 3.2r level. (B) Shown is the stereo-view of the active-site structure of RauA with the bound substrate (aurachin RE intermediate). Side-chains creating the
highly hydrophobic active-site pocket are shown as sticks and labeled. The side-chains of Lys66 and Arg305 interacting with quinolone oxygen and heme propionate group
are also shown. The models for the BC-loop, FG-loop, aI, bF, and C-terminal loop are colored in light blue, dark blue, red, green, and cyan, respectively. The proximal cysteine
ligand (Cys361) is also shown in magenta.
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classiﬁed as a new clan, namely, CYP1050 (Nelson, D.R., personal
communication).
3.4. Aurachin binding mode of RauA
Structural analysis showed clear electron density for the bound
substrate, which ﬁtted well to the aurachin RE intermediate model
(Fig. 4A). The aurachin RE intermediate was accommodated in the
highly hydrophobic active-site pocket created by the side-chains of
Phe73, Phe74, Phe68, Phe88, Leu186, and Leu399 (Fig. 4B). The far-
nesyl chain moiety of the aurachin curled into a U-shape topology,
i.e., the distance between the C12 and C24 located at each end of
the farnesyl group is approximately 3.3 Å. In addition, the hydro-
phobic side chains of Leu77, Ile188, Phe190, Met325, and Met397
are clustered at the top of the active-site pocket, which completely
closes the active-site pocket and shelters the bound substrate from
the solvent. There could be another conformational state that
opens the active site and is required for substrate entry and egress.
The quinolone ring of the aurachin RE intermediate is located
roughly parallel to the porphyrin plane of the heme via stacking
interactions, with a distance of approximately 3.4 Å. The quinolone
ring is also stabilized by two hydrogen bonds. One is formed be-
tween the carbonyl oxygen of the quinolone ring and the amino
nitrogen of the Lys66, with a distance of 2.9 Å. The amino nitrogen
of Lys66 also interacts with one of the propionate groups of the
heme. The other is formed between the nitrogen of the quinolone
ring and the solvent molecule (Wat601) with a distance of 3.0 Å.
The solvent also interacts with the main chain oxygen of Ala253
(2.9 Å) and the heme iron (2.5 Å). The nearest quinolone atom from
the heme iron is the nitrogen (4.3 Å), which is consistent with RauA
catalyzing the hydroxylation of the nitrogen atom. The existence of
the solvent molecule at the sixth ligand position of the heme iron is
also consistent with the results of the substrate-binding spectral
assay, i.e., the spin state of the heme iron did not completely shift
to the high-spin state in the presence of the substrate. The hydro-
gen bond with substrate nitrogen atom might allow the solvent to
remain as a ligand to the heme iron in the substrate-bound struc-
ture. It is generally thought that the solvent needs to move away in
order for the reduction of the heme iron and subsequent molecular
oxygen binding, the steps of which are crucial for initiating theP450 catalytic cycle. Thus, there may be a hidden structural mech-
anism, such as a subtle local conformational change to expel the
water, to promote catalytic turnover. The N-hydroxylating P450s
are uncommon, and only a couple of mammalian P450s such as
CYP1A2 are known to catalyze N-hydroxylation of aromatic
amines. To date, several high-energy reaction intermediate models
for amine N-hydroxylation have been proposed [42,43]. In contrast
to these, RauA hydroxylates the nitrogen atom in the quinolone
ring structure, a reaction that is geometrically distinct from the
amine N-hydroxylation. The structure of RauA reported in this
study may serve as an atomic model for further studies with
molecular dynamics simulation and computational chemistry.
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